• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    J.P. Morgan Life Sciences Private Capital Welcomes Dashyant Dhanak, Ph.D. as Venture Partner

    5/19/25 10:00:00 AM ET
    $JPM
    Major Banks
    Finance
    Get the next $JPM alert in real time by email

    NEW YORK, May 19, 2025 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital, the life sciences venture and growth equity arm within J.P. Morgan Asset Management, today announced the appointment of Dashyant (Dash) Dhanak, Ph.D., as Venture Partner. Dr. Dhanak will leverage his deep scientific and operational experience in therapeutics research and development to build and grow companies with Life Sciences Private Capital.

    Dashyant (Dash) Dhanak, Ph.D.

    Dr. Dhanak is a seasoned pharmaceutical research and development expert with over 30 years of experience. Most recently, Dr. Dhanak was the Chief Scientific Officer at Deciphera Pharmaceuticals, which was acquired by Ono Pharmaceuticals in 2024. Prior to his role at Deciphera, Dr. Dhanak served as Chief Scientific Officer at Incyte, where he was responsible for overseeing the research and preclinical development of innovative medicines across the company's hematology, oncology, and immunology franchises. During his tenure at Incyte, he contributed significantly to the filing of over fifteen Investigational New Drug (IND) applications. Before joining Incyte in 2018, Dr. Dhanak was Vice President and Global Head of Discovery Sciences at Johnson & Johnson's (J&J) Janssen Research & Development group. Prior to J&J, he spent 25 years at GlaxoSmithKline.

    "Dr. Dhanak has a proven track record of building and establishing leading biotech companies with scientific and operational excellence," said Dr. Stephen Squinto, CIO of Life Sciences Private Capital. "We are excited to welcome Dr. Dhanak to the team, and know he will play an essential role as our platform continues to grow."

    Biography

    Dashyant Dhanak, Ph.D., was most recently Chief Scientific Officer at Deciphera Pharmaceuticals, a company focused on developing innovative medicines for cancer treatment, until its successful sale to Ono Pharmaceuticals in 2024 for $2.4 billion. Prior to Deciphera, Dr. Dhanak served as Chief Scientific Officer at Incyte, where he oversaw the research and preclinical  development of groundbreaking medicines across hematology, oncology, and immunology franchises. Under his leadership, Incyte filed over fifteen Investigational New Drug (IND) applications, contributing to the company's robust pipeline of innovative therapies. Before joining Incyte in 2018, Dr. Dhanak was Vice President and Global Head of Discovery Sciences at Johnson & Johnson's Janssen Research & Development group where he led efforts in drug discovery and development. He also spent 25 years at GlaxoSmithKline, culminating in his role as Vice President and Head of the Cancer Epigenetics Discovery Performance Unit where he advanced research in cancer treatments. Dr. Dhanak holds a B.Sc. in Chemistry from the University of Manchester Institute of Science and Technology and a Ph.D. from the University of London. He completed his postdoctoral research in Natural Product Synthesis at Northwestern University.

    About J.P. Morgan Life Sciences Private Capital

    J.P. Morgan Life Sciences Private Capital ("LSPC"), is the life sciences platform of J.P. Morgan Private Capital, the investment arm for private companies across the capital structure with a focus on venture and growth investing within J.P. Morgan Asset Management. LSPC partners with leading early-stage biotherapeutics and late-stage healthcare companies. The early stage biotechnology practice is focused on company creation, Seed and Series A investments across all therapeutic areas in biotechnology. The late-stage healthcare practice is focused on Series B through pre-IPO investments within biotechnology, medical devices, tools, diagnostics, healthcare technology and pharmaceutical services.

    About J.P. Morgan Asset Management

    J.P. Morgan Asset Management, with assets under management of $3.7 trillion (as of 3/31/2025), is a global leader in investment management. J.P. Morgan Asset Management's clients include institutions, retail investors and high net worth individuals in every major market throughout the world. J.P. Morgan Asset Management offers global investment management in equities, fixed income, real estate, hedge funds, private equity and liquidity. For more information, visit: www.jpmorgan.com/am

    JPMorgan Chase & Co. (NYSE: JPM) is a leading financial services firm based in the United States of America ("U.S."), with operations worldwide. JPMorganChase had $4.4 trillion in assets and $351 billion in stockholders' equity (as of 3/31/2025). The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing and asset management. Under the J.P. Morgan and Chase brands, the Firm serves millions of customers in the U.S., and many of the world's most prominent corporate, institutional and government clients globally. Information about JPMorgan Chase & Co. is available at www.jpmorganchase.com.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/jp-morgan-life-sciences-private-capital-welcomes-dashyant-dhanak-phd-as-venture-partner-302458745.html

    SOURCE J.P. Morgan Asset Management

    Get the next $JPM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JPM

    DatePrice TargetRatingAnalyst
    7/9/2025$327.00Mkt Perform → Outperform
    Keefe Bruyette
    7/8/2025$259.00Hold → Reduce
    HSBC Securities
    6/27/2025$235.00Neutral → Underperform
    Robert W. Baird
    5/15/2025$305.00Buy
    TD Cowen
    3/7/2025$215.00 → $220.00Underperform → Neutral
    Robert W. Baird
    1/3/2025$269.00Peer Perform → Outperform
    Wolfe Research
    11/20/2024Outperform → Perform
    Oppenheimer
    11/7/2024$200.00Neutral → Underperform
    Robert W. Baird
    More analyst ratings

    $JPM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Burke Stephen B was granted 178 shares, increasing direct ownership by 0.10% to 184,881 units (SEC Form 4)

    4 - JPMORGAN CHASE & CO (0000019617) (Issuer)

    10/1/25 4:15:44 PM ET
    $JPM
    Major Banks
    Finance

    Director Novakovic Phebe N was granted 119 shares, increasing direct ownership by 0.99% to 12,120 units (SEC Form 4)

    4 - JPMORGAN CHASE & CO (0000019617) (Issuer)

    10/1/25 4:15:47 PM ET
    $JPM
    Major Banks
    Finance

    Director Rometty Virginia M was granted 111 shares, increasing direct ownership by 0.83% to 13,549 units (SEC Form 4)

    4 - JPMORGAN CHASE & CO (0000019617) (Issuer)

    10/1/25 4:15:49 PM ET
    $JPM
    Major Banks
    Finance

    $JPM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JPMorgan Chase upgraded by Keefe Bruyette with a new price target

    Keefe Bruyette upgraded JPMorgan Chase from Mkt Perform to Outperform and set a new price target of $327.00

    7/9/25 8:15:06 AM ET
    $JPM
    Major Banks
    Finance

    JPMorgan Chase downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded JPMorgan Chase from Hold to Reduce and set a new price target of $259.00

    7/8/25 8:30:31 AM ET
    $JPM
    Major Banks
    Finance

    JPMorgan Chase downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded JPMorgan Chase from Neutral to Underperform and set a new price target of $235.00

    6/27/25 7:46:30 AM ET
    $JPM
    Major Banks
    Finance

    $JPM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Carbon Direct and JPMorganChase Release Principles for Optimizing for Biodiversity in Nature-Based Voluntary Carbon Market Projects

    Carbon Direct, a global leader in science-driven carbon management, in collaboration with JPMorganChase, today unveiled a new report: Optimizing for Biodiversity with Nature-Based Projects in the Voluntary Carbon Market: Principles for Pursuing Dual Outcomes. This guide offers organizations a data-driven blueprint for identifying and designing nature-based voluntary carbon market (VCM) projects that deliver both carbon and biodiversity outcomes. Current VCM structures are primarily carbon-focused, and despite growing buyer demand, effectively integrating both carbon and biodiversity outcomes remains a complex challenge for the market. The nature of projects grounded in land management, ho

    10/16/25 6:00:00 AM ET
    $JPM
    Major Banks
    Finance

    JPMorganChase Declares Preferred Stock Dividends

    JPMorgan Chase & Co. (NYSE:JPM) ("JPMorganChase" or the "Firm") has declared dividends on the outstanding shares of the Firm's Series DD, EE, GG, JJ, KK, LL, MM and NN preferred stock. Information can be found on the Firm's Investor Relations website at https://www.jpmorganchase.com/ir/news. JPMorgan Chase & Co. (NYSE:JPM) is a leading financial services firm based in the United States of America ("U.S."), with operations worldwide. JPMorganChase had $4.6 trillion in assets and $360 billion in stockholders' equity as of September 30, 2025. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing

    10/15/25 4:31:00 PM ET
    $JPM
    Major Banks
    Finance

    New Cohort of U.S. Veteran and Military-Spouse Business Leaders Selected for CEOcircle Program

    Sixty entrepreneurs will gain access to resources and networking through the Syracuse University IVMF and J.P. Morgan Commercial Banking program. Today, Syracuse University's D'Aniello Institute for Veteran & Military Families (IVMF) and J.P. Morgan Commercial Banking announced the new cohort of 60 business leaders selected for CEOcircle, a yearlong peer accountability training program tailored to help mid-size veteran and military spouse executives scale their businesses. Since launching their joint effort to support veteran and military spouse founders in 2021, J.P. Morgan Commercial Banking and the IVMF have guided over 250 business owners through CEOcircle, a program that helps part

    10/15/25 9:00:00 AM ET
    $JPM
    Major Banks
    Finance

    $JPM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Jpmorgan Chase & Co sold 14 shares and bought $51 worth of shares (14 units at $3.67) (SEC Form 4)

    4 - JPMORGAN CHASE & CO (0000019617) (Reporting)

    4/11/25 4:55:53 PM ET
    $JPM
    Major Banks
    Finance

    $JPM
    SEC Filings

    View All

    SEC Form FWP filed by JP Morgan Chase & Co.

    FWP - JPMORGAN CHASE & CO (0000019617) (Subject)

    10/17/25 2:03:20 PM ET
    $JPM
    Major Banks
    Finance

    SEC Form FWP filed by JP Morgan Chase & Co.

    FWP - JPMORGAN CHASE & CO (0000019617) (Subject)

    10/16/25 8:57:58 PM ET
    $JPM
    Major Banks
    Finance

    SEC Form FWP filed by JP Morgan Chase & Co.

    FWP - JPMORGAN CHASE & CO (0000019617) (Subject)

    10/16/25 6:39:47 PM ET
    $JPM
    Major Banks
    Finance

    $JPM
    Leadership Updates

    Live Leadership Updates

    View All

    J.P. Morgan Life Sciences Private Capital Welcomes Dashyant Dhanak, Ph.D. as Venture Partner

    NEW YORK, May 19, 2025 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital, the life sciences venture and growth equity arm within J.P. Morgan Asset Management, today announced the appointment of Dashyant (Dash) Dhanak, Ph.D., as Venture Partner. Dr. Dhanak will leverage his deep scientific and operational experience in therapeutics research and development to build and grow companies with Life Sciences Private Capital. Dr. Dhanak is a seasoned pharmaceutical research and development expert with over 30 years of experience. Most recently, Dr. Dhanak was the Chief Scienti

    5/19/25 10:00:00 AM ET
    $JPM
    Major Banks
    Finance

    J.P. Morgan Asset Management Focuses on Generational Opportunities in Real Estate, Appointing Chad Tredway as Global Head

    New role unifies asset manager's global real estate offering and expands access to firmwide capabilities NEW YORK, May 14, 2025 /PRNewswire/ -- J.P. Morgan Asset Management is enhancing its real estate business with the appointment of Chad Tredway as Global Head of Real Estate. In this new role, he will oversee real estate operations across the Americas, Europe, and Asia Pacific, increasing the firm's global reach and ability to deliver innovative investment opportunities. Mr. Tredway has a proven track record of managing real estate assets for retail and institutional client

    5/14/25 12:00:00 PM ET
    $JPM
    Major Banks
    Finance

    Campbell Global Announces Leadership Transition: Angie Davis to Succeed John Gilleland as CEO

    PORTLAND, Ore., May 12, 2025 /PRNewswire/ -- Campbell Global, a leader in forestland investing and management, and a vital part of J.P. Morgan Asset Management's $400 billion alternatives business, is pleased to announce a significant leadership transition. Angie Davis, currently serving as President of Campbell Global, will succeed John Gilleland as Chief Executive Officer, effective October 1. Campbell Global, a pioneer in timberland investing, has been a full-service investment advisor focusing solely on commercial forestlands and related assets. Operating in core forest in

    5/12/25 3:00:00 PM ET
    $JPM
    Major Banks
    Finance

    $JPM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by JP Morgan Chase & Co.

    SC 13D - JPMORGAN CHASE & CO (0000019617) (Filed by)

    9/12/24 2:46:34 PM ET
    $JPM
    Major Banks
    Finance

    Amendment: SEC Form SC 13G/A filed by JP Morgan Chase & Co.

    SC 13G/A - JPMORGAN CHASE & CO (0000019617) (Filed by)

    8/9/24 1:40:34 PM ET
    $JPM
    Major Banks
    Finance

    SEC Form SC 13G/A filed by JP Morgan Chase & Co. (Amendment)

    SC 13G/A - JPMORGAN CHASE & CO (0000019617) (Subject)

    2/13/24 4:55:49 PM ET
    $JPM
    Major Banks
    Finance

    $JPM
    Financials

    Live finance-specific insights

    View All

    JPMorganChase Declares Preferred Stock Dividends

    JPMorgan Chase & Co. (NYSE:JPM) ("JPMorganChase" or the "Firm") has declared dividends on the outstanding shares of the Firm's Series DD, EE, GG, JJ, KK, LL, MM and NN preferred stock. Information can be found on the Firm's Investor Relations website at https://www.jpmorganchase.com/ir/news. JPMorgan Chase & Co. (NYSE:JPM) is a leading financial services firm based in the United States of America ("U.S."), with operations worldwide. JPMorganChase had $4.6 trillion in assets and $360 billion in stockholders' equity as of September 30, 2025. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing

    10/15/25 4:31:00 PM ET
    $JPM
    Major Banks
    Finance

    JPMorganChase to Host Third-Quarter 2025 Earnings Call

    As previously announced, JPMorgan Chase & Co. (NYSE:JPM) ("JPMorganChase" or the "Firm") will host a conference call to review third-quarter 2025 financial results on Tuesday, October 14, 2025 at 8:30 a.m. (ET). The results are scheduled to be released at approximately 7:00 a.m. (ET). The live audio webcast and presentation slides will be available on www.jpmorganchase.com under Investor Relations, Events & Presentations. JPMorganChase will notify the public that financial results have been issued through its social media outlet @JPMorgan and @Chase on X, and by a press release over Business Wire that will provide the link to the Firm's Investor Relations website. In addition to being ava

    9/16/25 4:34:00 PM ET
    $JPM
    Major Banks
    Finance

    JPMorganChase Declares Common Stock Dividend

    JPMorgan Chase & Co. (NYSE:JPM) ("JPMorganChase" or the "Firm") declared a quarterly dividend on the outstanding shares of the common stock of JPMorganChase. Information can be found on the Firm's Investor Relations website at https://www.jpmorganchase.com/ir/news. JPMorgan Chase & Co. (NYSE:JPM) is a leading financial services firm based in the United States of America ("U.S."), with operations worldwide. JPMorganChase had $4.6 trillion in assets and $357 billion in stockholders' equity as of June 30, 2025. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing and asset management. Under the

    9/16/25 4:33:00 PM ET
    $JPM
    Major Banks
    Finance